NO20032788D0 - Modafinil-forbindelse og cyklodekstrinblandinger - Google Patents

Modafinil-forbindelse og cyklodekstrinblandinger

Info

Publication number
NO20032788D0
NO20032788D0 NO20032788A NO20032788A NO20032788D0 NO 20032788 D0 NO20032788 D0 NO 20032788D0 NO 20032788 A NO20032788 A NO 20032788A NO 20032788 A NO20032788 A NO 20032788A NO 20032788 D0 NO20032788 D0 NO 20032788D0
Authority
NO
Norway
Prior art keywords
modafinil compound
cyclodextrin
cyclodextrin mixtures
mixtures
modafinil
Prior art date
Application number
NO20032788A
Other languages
English (en)
Other versions
NO20032788L (no
Inventor
Martin J Jacobs
Piyush R Patel
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO20032788D0 publication Critical patent/NO20032788D0/no
Publication of NO20032788L publication Critical patent/NO20032788L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, ***e
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NO20032788A 2000-12-19 2003-06-18 Modafinil-forbindelse og cyklodekstrinblandinger NO20032788L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25668100P 2000-12-19 2000-12-19
US10/023,441 US7141555B2 (en) 2000-12-19 2001-12-18 Modafinil compound and cyclodextrin mixtures
PCT/US2001/049189 WO2002056915A2 (en) 2000-12-19 2001-12-19 Complex of modafinil and cyclodextrin

Publications (2)

Publication Number Publication Date
NO20032788D0 true NO20032788D0 (no) 2003-06-18
NO20032788L NO20032788L (no) 2003-07-07

Family

ID=26697157

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032788A NO20032788L (no) 2000-12-19 2003-06-18 Modafinil-forbindelse og cyklodekstrinblandinger

Country Status (23)

Country Link
US (1) US7141555B2 (no)
EP (1) EP1368063B1 (no)
JP (1) JP4094428B2 (no)
KR (1) KR20040012696A (no)
CN (1) CN100384477C (no)
AT (1) ATE396745T1 (no)
AU (1) AU2002246711B2 (no)
BG (1) BG108009A (no)
BR (1) BR0116698A (no)
CA (1) CA2432126C (no)
CZ (1) CZ20031878A3 (no)
DE (1) DE60134274D1 (no)
EA (1) EA200300705A1 (no)
ES (1) ES2305128T3 (no)
HK (1) HK1059055A1 (no)
HU (1) HUP0401592A2 (no)
IL (1) IL156470A0 (no)
MX (1) MXPA03005505A (no)
NO (1) NO20032788L (no)
NZ (1) NZ526780A (no)
PL (1) PL362474A1 (no)
SK (1) SK9012003A3 (no)
WO (1) WO2002056915A2 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1494998A2 (en) 2002-03-01 2005-01-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
JP2004250390A (ja) * 2003-02-21 2004-09-09 Taisho Pharmaceut Co Ltd 鉄化合物配合内服液剤
JP5412709B2 (ja) 2003-03-28 2014-02-12 アレス トレーディング ソシエテ アノニム 改良された経口及び経粘膜デリバリーのためのクラドリビン製剤
KR101129816B1 (ko) * 2003-03-28 2012-03-26 아레스 트레이딩 에스.아. 클라드리빈의 경구용 제형
MXPA06002507A (es) * 2003-09-04 2006-06-20 Cephalon Inc Composiciones de modafinil.
CN1874993B (zh) * 2003-09-04 2010-12-08 赛福伦公司 莫达芬尼组合物
US7566805B2 (en) 2003-09-04 2009-07-28 Cephalon, Inc. Modafinil compositions
US8153159B2 (en) 2003-09-18 2012-04-10 Cephalon, Inc. Modafinil modified release pharmaceutical compositions
US20090018202A1 (en) 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
CA2565159A1 (en) * 2004-05-06 2005-12-15 Cydex, Inc. Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
JP2009543803A (ja) * 2006-07-12 2009-12-10 エラン・ファルマ・インターナショナル・リミテッド モダフィニルのナノ粒子製剤
JP2009091309A (ja) * 2007-10-10 2009-04-30 Japan Organo Co Ltd バコパモニエラエキスを含有する組成物およびその製造方法ならびに飲食品
WO2010053487A1 (en) 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2011043630A2 (ko) * 2009-10-08 2011-04-14 (주)송호바이오메드 고 수용성 2-하이드록시프로필-베타사이클로덱스트린을 유효성분으로 함유하는 비만 질환 예방 및 치료용 조성물
KR101026864B1 (ko) * 2009-10-08 2011-04-12 (주)송호바이오메드 고 수용성 2―하이드록시프로필―베타사이클로덱스트린을 유효성분으로 함유하는 비만 질환 예방 및 치료용 조성물
AU2011302293B2 (en) 2010-09-13 2015-11-26 Bev-Rx, Inc. Aqueous drug delivery system comprising off - flavor masking agent
US9474715B2 (en) 2011-11-30 2016-10-25 Andreas Voigt Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
US9364549B2 (en) 2011-11-30 2016-06-14 Andreas Voigt Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement
KR101719987B1 (ko) 2015-08-03 2017-03-27 (주)상전정공 화물차량의 잠금장치
US9855228B1 (en) 2016-12-14 2018-01-02 Taho Pharmaceuticals Ltd. Oral solution comprising atomoxetine hydrochloride and methods thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5835968B2 (ja) * 1974-02-25 1983-08-05 帝人株式会社 サイクロデキストリン包接化合物の製造法
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
JPS5920230A (ja) 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
JPS62281855A (ja) * 1986-05-29 1987-12-07 Daikin Ind Ltd ビタミン,ビタミン誘導体,またはホルモンを含有する包接化合物
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
JPH035438A (ja) * 1989-05-31 1991-01-11 Kaken Pharmaceut Co Ltd フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤
SE8902235D0 (sv) * 1989-06-20 1989-06-20 Haessle Ab Novel cyclodextrin inclusion complexes
FR2663225B1 (fr) 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
US5024997A (en) 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
FR2684875B1 (fr) * 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2702968B1 (fr) * 1993-03-23 1995-06-23 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
US5843347A (en) 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
US5866162A (en) 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
US6077871A (en) 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) * 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation

Also Published As

Publication number Publication date
WO2002056915A2 (en) 2002-07-25
CZ20031878A3 (cs) 2004-10-13
NZ526780A (en) 2005-07-29
ES2305128T3 (es) 2008-11-01
PL362474A1 (en) 2004-11-02
JP4094428B2 (ja) 2008-06-04
JP2004525104A (ja) 2004-08-19
KR20040012696A (ko) 2004-02-11
CA2432126C (en) 2011-03-08
IL156470A0 (en) 2004-01-04
EP1368063A2 (en) 2003-12-10
EA200300705A1 (ru) 2003-12-25
EP1368063B1 (en) 2008-05-28
DE60134274D1 (en) 2008-07-10
HUP0401592A2 (hu) 2004-11-29
CN1486196A (zh) 2004-03-31
HK1059055A1 (en) 2004-06-18
US20020160982A1 (en) 2002-10-31
SK9012003A3 (en) 2003-12-02
BR0116698A (pt) 2003-10-21
NO20032788L (no) 2003-07-07
ATE396745T1 (de) 2008-06-15
CA2432126A1 (en) 2002-07-25
US7141555B2 (en) 2006-11-28
CN100384477C (zh) 2008-04-30
BG108009A (en) 2004-09-30
MXPA03005505A (es) 2003-10-06
AU2002246711B2 (en) 2006-12-14
WO2002056915A3 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
NO20032788D0 (no) Modafinil-forbindelse og cyklodekstrinblandinger
ATE264863T1 (de) 28-epirapaloge
CY1106056T1 (el) Παραγωγα 2-αμινο-2-αλκυλ-5-επτενοϊκου και επτυνοϊκου οξεος χρησιμα σαν αναστολεις συνθασης νιτρικου οξειδιου
DE60112893T2 (de) Quetschventil
CY1110061T1 (el) Συνθεσεις περιλαμβανοντας ενωσεις μοδαφινιλης
CY2013016I2 (el) Διαλυμα ακετονης διμεθοξυ δοσεταξελης και η διαδικασια παρασκευης του
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
ATE372372T1 (de) Zusammensetzungen enthaltend cyclodextrin
DK1511734T3 (da) Forbindelser, præparater og fremgangsmåder
IS8219A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
CY1107485T1 (el) 3-θειομεθυλπυραζoλες ως παρασιτοκτoνα
DK1322654T3 (da) Platinkomplekser som antitumormidler
ATE325135T1 (de) 2-alkylierte cyclodextrinderivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung
NO20053588D0 (no) Acylaminotiazol-derivater, fremstilling og anvendelse derav som beta-amyloidpeptid-produksjonsinhibitorer.
ATE309220T1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2- carbonsäurederivate
NO20014752D0 (no) Taksanpreparater med forbedret opplöselighet
FR2806446B1 (fr) Turbocompresseur
ATE317386T1 (de) Dihydroindol- und tetrahydrochinolinderivate
ATE293126T1 (de) Cyclische hexapeptidderivate
NO20055142D0 (no) Diarylmetylidenpiperidinderivater, fremstillinger og anvendelser derav
DE50305183D1 (de) Perlglänzende wässrige Zubereitungen
NO20021429D0 (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
DE50310743D1 (de) Wässrige formulierungen von (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4- trifluorbutan-1-sulfonat
FI20000395A (fi) N-(amidinobentsoyyli- tai amidinopyridyylikarbonyyli)-alfa-aminohappojohdannaisia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application